Novonesis increases its full year 2026 organic sales growth outlook from 5-7% to now 7-8% based on a stronger performance so far in the year and the expectations for the rest of the year. Following the stronger sales growth outlook, the adjusted EBITDA margin is now expected to be at the higher end of the 37-38% range.
Read more at globenewswire.comIncreased outlook for 2026
Barchart·08/19/2026 10:39:00
语音播报
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.